A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-26 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Pre-procedure, every patient used external vacuum expansion of the recipient-site tissues to create a breast tissue matrix to be injected with autologous fat grafts of adipocyte tissue, refined via low G-force centrifugation. Pre- and post-procedure, the breast volumes were measured; the patients underwent pre-procedure and 6-month post-procedure MRI and 3D volumetric imaging examinations. At six months post-procedure, each woman had a significant increase in breast volume, ranging 60–200 percent, per the MRI (n=12) examinations. The size, form, and feel of the breasts was natural; post-procedure MRI examinations revealed no oil cysts or abnormality (neoplasm) in the fat-augmented breasts. Moreover, given the sensitive, biologic nature of breast tissue, periodic MRI and 3-D volumetric imaging examinations are required to monitor the breast-tissue viability and the maintenance of the large volume (+300 cc) fat grafts.
=== Prenatal and newborn screening === Checking for sickle cell disease begins during pregnancy, with a prenatal screening questionnaire that includes, among other things, a consideration of health issues in the child's parents and close relatives. During pregnancy, genetic testing can be done on either a blood sample from the foetus or a sample of amniotic fluid. During the first trimester of pregnancy, chorionic villus sampling (CVS) is a technique used for prenatal diagnosis of sickle cell disease. A routine heel prick test, in which a small sample of blood is collected a few days after birth, is used to check conclusively for sickle cell disease as well as other inherited conditions.
Hayes (1904), pioneering cultural historian; former U.S. ambassador to Spain Edward Sapir (1904), linguist and co-creator of the Sapir–Whorf hypothesis Frank Speck (1904), anthropologist, professor at the University of Pennsylvania William Stuart Messer (1905), professor of Latin at Dartmouth College, recipient of a 1922 Rome Prize Mark Raymond Harrington (1907), curator at the Southwest Museum of the American Indian and owner of the Rómulo Pico Adobe Edwin Borchard (1908), international legal scholar; Sterling Professor at the Yale Law School Richard F. Bach (1909), curator with the Metropolitan Museum of Art Rhys Carpenter (1909), classical art historian and professor at Bryn Mawr College F. Stuart Chapin (1909), sociologist and former president of the American Sociological Association Harold Gould Henderson (1910), Japanologist and former president of the Japan Society, founder of the Haiku Society of America Armin K. Lobeck (1911), cartographer Carl Zigrosser (1911), curator of the Philadelphia Museum of Art Lawrence K. Frank (1912), social scientist; vice president of the Josiah Macy Jr.
Sources: en.wikipedia.org
=== Italy === The Italian Armed Forces use the "Razione Viveri Speciali da Combattimento", consisting of a heavy duty brownish-green plastic bag with three thin white cardboard cartons inside (one for breakfast, one for lunch and one for dinner), each containing meal items plus accessories. There are seven menus, called "modules", identified by colors: yellow, red, grey, green, white, pink and blue. Typically, breakfast consists of: a chocolate bar, fruit candy, crackers or sweet bread, instant coffee, sugar, and a tube of sweetened condensed milk. Lunch has: two pull-ring cans with precooked foods (Tortellini al Ragù, Pasta e Fagioli, Wurstel, Tacchino in Gelatina, Insalata di Riso, etc.), a small can of fruit cocktail, a multivitamin tablet, energy and fiber tablets, instant coffee, sugar, and a plastic spoon wrapped with a napkin. Dinner consists of two more meal cans plus crackers, an energy bar, instant coffee, and sugar. Accessories are: a folding stove, fuel tablets, water purification tablets, toothpick, matches, and three small disposable toothbrushes with pre-applied tooth powder.
=== Construction === Spent diatomaceous earth from the brewing process can be added to ceramic mass for the production of red bricks with higher open porosity. Diatomaceous earth is considered a prominent inorganic non-metallic material that can be used for the production of various ceramics, including production of porous ceramics under low temperature hydrothermal technology.
=== Selected publications === Ariely, Dan; Loewenstein, George; Prelec, Drazen (2003), "Coherent Arbitrariness: Stable demand curves without stable preferences", The Quarterly Journal of Economics, 118 (1): 73–106, doi:10.1162/00335530360535153, archived from the original on April 4, 2012 Ariely, Dan (2000), "Controlling information flow: Effects on consumers' decision making and preference", Journal of Consumer Research, 27 (2): 233–248, CiteSeerX 10.1.1.203.1798, doi:10.1086/314322 {{citation}}: Cite uses deprecated parameter |citeseerx= (help) Ariely, Dan; Wertenbroch, Klaus (2002), "Procrastination, Deadlines, and Performance: Self-Control by Precommitment" (PDF), Psychological Science, 13 (3): 219–224, doi:10.1111/1467-9280.00441, PMID 12009041, S2CID 3025329 Heyman, James; Ariely, Dan (2004), "Effort for Payment: A Tale of Two markets" (PDF), Psychological Science, 15 (11): 787–793(7), doi:10.1111/j.0956-7976.2004.00757.x, PMID 15482452, S2CID 8573184 Carmon, Ziv; Ariely, Dan (2000), "Focusing on the Forgone: Why Value can Appear so Different to Buyers and Sellers" (PDF), Journal of Consumer Research, 27 (3): 360–370, doi:10.1086/317590 Shiv, Baba; Carmon, Ziv; Ariely, Dan (2005), "Placebo Effects of Marketing Actions: Consumers May Get What They Pay For" (PDF), Journal of Marketing Research, XXII (4): 383–393, doi:10.1509/jmkr.2005.42.4.383, S2CID 14170707 Mazar, Nina; Ariely, Dan (2006), "Dishonesty in Everyday Life and Its Policy Implications" (PDF), Journal of Public Policy & Marketing, 25 (1): 117–126, doi:10.1509/jppm.25.1.117, S2CID 2813683 Lee, Leonard; Frederick, Shane; Ariely, Dan (2006), "Try it, you'll like it: The influence of expectation, consumption, and revelation on preferences for beer" (PDF), Psychological Science, 17 (12): 1054–1058, doi:10.1111/j.1467-9280.2006.01829.x, PMID 17201787, S2CID 1252769 Ariely, Dan; Gregory S. Berns (March 3, 2010). "Neuromarketing: the hope and hype of neuroimaging in business" (PDF). Nature Reviews Neuroscience. 11 (4): 284–292. doi:10.1038/nrn2795. PMC 2875927. PMID 20197790. Archived from the original (PDF) on July 11, 2013. Ariely, Dan; Michael I. Norton; Daniel Mochon (July 2012). "The IKEA effect: When labor leads to love" (PDF). Journal of Consumer Psychology. 3. 22 (3): 453–460. doi:10.1016/j.jcps.2011.08.002. Archived from the original (PDF) on May 20, 2014.
Intensive insulin therapy or flexible insulin therapy is a therapeutic regimen for diabetes mellitus treatment. This newer approach contrasts with conventional insulin therapy. Rather than minimize the number of insulin injections per day (a technique which demands a rigid schedule for food and activities), the intensive approach favors flexible meal times with variable carbohydrate as well as flexible physical activities. The trade-off is the increase from 2 or 3 injections per day to 4 or more injections per day, which was considered "intensive" relative to the older approach. In North America in 2004, many endocrinologists prefer the term "flexible insulin therapy" (FIT) to "intensive therapy" and use it to refer to any method of replacing insulin that attempts to mimic the pattern of small continuous basal insulin secretion of a working pancreas combined with larger insulin secretions at mealtimes. The semantic distinction reflects changing treatment.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.